[Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S. aureus pneumonia following A/California/04/2009 (H1N1) influenza virusinfection. Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.